All In MedTech

Device Trial Radar · NCT04203667

EndoRotor® Endoscopic Mucosal Resection System for the Colon

Prospective, Multicenter Study for the Evaluation of Safety and Performance of the Interscope EndoRotor Endoscopic Mucosal Resection System for the Removal of Alimentary Tract Mucosa in the Colon

Last checked: Nov 20, 2026Latest source record: Apr 5, 2022 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registry

Status

Completed

Enrollment

66

Actual

Start

Apr 18, 2018

Primary completion

Apr 5, 2020

Study completion Apr 5, 2020

Sponsor

Lead sponsor
Interscope, Inc.Not on our public-company list
Sponsor type
Industry
First posted
Dec 18, 2019

More device trials from this sponsor

Design

Study type
Interventional
Phase
Not applicable (typical for device studies)
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated device
Yes
Who can join
All sexes, from 18 years, up to 85 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The EndoRotor® is intended for use (USA labeling) in endoscopic procedures by a trained gastroenterologist to resect and remove tissue, not intended for biopsy, of the gastrointestinal (GI) system including post-endoscopic mucosal resection (EMR) tissue persistence with a scarred base and residual tissue from the peripheral margins following EMR. In this trial investigators will conduct a post-market, prospective, non-randomized, multi-center study for the treatment of subjects with the need for resection of recurrent flat or sessile colorectal lesions where EndoRotor is the primary resection modality of persistent adenoma with a scarred base.

Conditions

  • Polyp of Colon
  • Endoscopic Mucosal Resection
  • Recurrent Colon Adenoma

Interventions

  • EndoRotor ResectionDevice

    The EndoRotor® is a powered cutting cannula for the removal of alimentary tract mucosa. Cutting is performed by aspirating tissue into a rotating cutting window. The resected tissue is immediately aspirated away from the resection site and collected in the EndoRotor Specimen Trap. The tissue can then be sent for pathological examination using standard methods. The system consists of a power console, foot control, specimen trap with pre-loaded filter and the applied part, which is the single-use catheter.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Primary Effectiveness Endpoint Defined as the Ability of the EndoRotor to Resect Lesions Without Concomitant Use of Other Resection Modalities and With no Device-related Serious Adverse Events Through the 90 Day Post Procedure Follow-up Visit.Time frame: Index Procedure through 90 Day Post Procedure Follow-up Visit
  2. Primary Safety Analysis Defined as the Occurrence of Serious Adverse Events Related to the EndoRotor Device as Measured From the Index Procedure Through the 90 Day Post Procedure Follow-up Visit.Time frame: Index Procedure through 90 Day Post Procedure Follow-up Visit

Locations

11 sites in 4 countries. Site status is shown where the registry gives one.

  • Geisinger Medical Center

    Danville, Pennsylvania

  • Centre Hospitalier Universitaire (CHU)

    Angers, France

  • Hopital Edouard Herriot

    Lyon, France

8 more study sites with a free account

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.